SCHEMBL4292884

SCHEMBL4292884

NC(=O)CC[C@H](NCC(=O)C(=O)O)C(=O)O

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.44
ALOX15 P16050 1/20 0.44
BLM P54132 1/20 0.44
PMP22 Q01453 1/20 0.44
MMP2 P08253 2/20 0.43
MMP9 P14780 2/20 0.43
CA2 P00918 5/20 0.42
CA1 P00915 4/20 0.42
FOLH1 Q04609 4/20 0.37
RIMKLA Q8IXN7 1/20 0.37
NAALAD2 Q9Y3Q0 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
GGT1 P19440 1/20 0.35
BMP1 P13497 1/20 0.33
GGH Q92820 1/20 0.33
TGFBR1 P36897 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cysteine SCHEMBL4587284 0.88 KMT2A (0.46) KMT2AALOX15BLMPMP22MMP2
SCHEMBL6554061 0.85 KMT2A (0.47) KMT2AALOX15BLMPMP22MMP2
SCHEMBL21802287 0.85 KMT2A (0.47) KMT2AALOX15BLMPMP22MMP2
SCHEMBL3651670 0.85 FOLH1 (0.53) MMP9FOLH1RIMKLANAALAD2GGH
Cysteine SCHEMBL4586359 0.83 KMT2A (0.41) KMT2AALOX15BLMPMP22MMP2
SCHEMBL2177303 0.83 KMT2A (0.45) KMT2AALOX15BLMPMP22MMP2
SCHEMBL28142279 0.83 KMT2A (0.45) KMT2AALOX15BLMPMP22MMP2
SCHEMBL8768913 0.82 KMT2A (0.48) KMT2AALOX15BLMPMP22MMP2
SCHEMBL8768917 0.82 KMT2A (0.48) KMT2AALOX15BLMPMP22MMP2
SCHEMBL4397483 0.81 KMT2A (0.44) KMT2AALOX15BLMPMP22MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4163383-A1 MICROBIAL PRODUCTION OF FATTY AMINES Genomatica, Inc. (US) 2023-04-12 EP disclosed
EP-3647430-B1 MICROBIAL PRODUCTION OF FATTY AMINES GENOMATICA INC (US) 2022-10-26 EP disclosed
CN-115151636-A Engineered erythroid cells comprising HLA-G polypeptides and methods of use thereof 鲁比厄斯治疗法股份有限公司 2022-10-04 CN disclosed
US-8378071-B2 Peptide epitopes of VEGFR-2/KDR that inhibit angiogenesis THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2013-02-19 US disclosed
US-20090247467-A1 PEPTIDE EPITOPES OF VEGFR-2/KDR THAT INHIBIT ANGIOGENESIS THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF 2009-10-01 US disclosed
US-20060234941-A1 Peptide epitopes of VEGFR-2/KDR that inhibit angiogenesis THE GOV. OF THE USA AS REPRESENTED BY THE SECRETARY OF THE DEPT. OF HEALTH & HUMAN SERVICES 2006-10-19 US disclosed
US-20060088509-A1 Isolated clk-1 -/- cells from clk-1 heterozygous animals and their use in treating oxidative stress disorders MCGILL UNIVERSITY (CA) 2006-04-27 US disclosed
WO-2006037224-A1 ISOLATED CLK-1 -I- CELLS FROM CLK-1 HETEROZYGOUS ANIMALS AND THEIR USE IN TREATING OXIDATIVE STRESS DISORDERS MCGILL UNIVERSITY (CA) 2006-04-13 WO disclosed
CN-1460109-A Improved specificity in treatment of diseases RIBA PHARMACEUTICALS INC (US) 2003-12-03 CN disclosed
WO-2002031123-A1 STEM CELLS THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) 2002-04-18 WO disclosed
US-6228589-B1 MONITORING POISONING; INCUBATE ANIMAL WITH MODULATOR, EXTRACT MESSENGER NUCLEIC ACIDS, FORMING COMPLEMENTARY DEOXYRIBONUCLEIC ACIDS, SEQUENCE NUCLEOTIDE SEQUENCE AND MONITOR FREQUENCY DISTRIBUTION OF EXPRESSED GENES LYNX THERAPEUTICS, INC. 2001-05-08 US disclosed